BL-M24D1
/ Biokin Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
January 31, 2026
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of BL-M24D1 for Injection in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
(ChiCTR)
- P1 | N=63 | Recruiting | Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
January 01, 2026
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
(clinicaltrials.gov)
- P1 | N=16 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck
December 14, 2025
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
(clinicaltrials.gov)
- P1 | N=33 | Not yet recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
New P1 trial • Gastrointestinal Cancer • Solid Tumor
December 02, 2025
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=33 | Not yet recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology
November 25, 2025
BL-M24D1-101: A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
(clinicaltrials.gov)
- P1 | N=33 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
November 19, 2025
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
(clinicaltrials.gov)
- P1 | N=16 | Not yet recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
New P1 trial • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck
November 19, 2025
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
(clinicaltrials.gov)
- P1 | N=33 | Not yet recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
October 22, 2025
Sichuan Biokin Pharmaceutical…announced that the National Medical Products Administration (NMPA) has approved its novel antibody‑drug conjugate (ADC), BL‑M24D1, to enter clinical trials as a monotherapy
(flcube.com)
- "The drug is indicated for patients with relapsed or refractory hematological malignancies and advanced solid tumors."
New trial • Hematological Malignancies • Solid Tumor
1 to 8
Of
8
Go to page
1